Cowpox to COVID: History of vaccination in the immunocompromised host.
COVID
T cell
immunology
immunosuppression
solid organ transplantation
vaccination
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
10
02
2023
received:
30
11
2022
accepted:
12
02
2023
medline:
19
6
2023
pubmed:
9
4
2023
entrez:
8
4
2023
Statut:
ppublish
Résumé
The use of vaccination to prevent infection has a long history, starting in the 1700s with Jenner. New innovations have led to improvements in the safety and efficacy of vaccines, from live attenuated viruses to subunit vaccines, to RNA-based vaccination for SARS-CoV-2. Despite this progress, however, solid organ transplant (SOT) recipients on immunosuppression demonstrate an impaired vaccine response compared with healthy controls. This issue is important given the increased vulnerability to infection in immunocompromised patients, especially in the setting of the Coronavirus Disease 2019 (COVID-19) pandemic. We reviewed the literature on key topics in vaccination with significant clinical impact on SOT patients. Prior to COVID-19, a large amount of data has been published demonstrating impaired humoral and T-cell responses to multiple vaccinations targeting influenza, hepatitis B, VZV, and Pneumococcus. Poor immunogenicity can be addressed through the use of adjuvants to boost the immune response, even in the setting of senescence related to age or immunosuppression. New vaccines provide hope for preventing infection due to hepatitis C and Cytomegalovirus, and to the emerging infection, monkeypox. The data on the impact of the COVID-19 vaccine in SOT patients is reviewed, with a focus on seroconversion, antibody titer, and antigen-specific T cells. Factors associated with impaired response, including mycophenolate, are described. The history of vaccination demonstrates how scientific breakthroughs can be applied to clinical challenges. New approaches using adjuvants, strategic antigen selection, and RNA-based vaccines offer the potential to improve immune response in SOT recipients. Future innovations are needed to better protect the vulnerable immunocompromised host.
Sections du résumé
BACKGROUND
BACKGROUND
The use of vaccination to prevent infection has a long history, starting in the 1700s with Jenner. New innovations have led to improvements in the safety and efficacy of vaccines, from live attenuated viruses to subunit vaccines, to RNA-based vaccination for SARS-CoV-2. Despite this progress, however, solid organ transplant (SOT) recipients on immunosuppression demonstrate an impaired vaccine response compared with healthy controls. This issue is important given the increased vulnerability to infection in immunocompromised patients, especially in the setting of the Coronavirus Disease 2019 (COVID-19) pandemic.
METHODS
METHODS
We reviewed the literature on key topics in vaccination with significant clinical impact on SOT patients.
RESULTS
RESULTS
Prior to COVID-19, a large amount of data has been published demonstrating impaired humoral and T-cell responses to multiple vaccinations targeting influenza, hepatitis B, VZV, and Pneumococcus. Poor immunogenicity can be addressed through the use of adjuvants to boost the immune response, even in the setting of senescence related to age or immunosuppression. New vaccines provide hope for preventing infection due to hepatitis C and Cytomegalovirus, and to the emerging infection, monkeypox. The data on the impact of the COVID-19 vaccine in SOT patients is reviewed, with a focus on seroconversion, antibody titer, and antigen-specific T cells. Factors associated with impaired response, including mycophenolate, are described.
CONCLUSION
CONCLUSIONS
The history of vaccination demonstrates how scientific breakthroughs can be applied to clinical challenges. New approaches using adjuvants, strategic antigen selection, and RNA-based vaccines offer the potential to improve immune response in SOT recipients. Future innovations are needed to better protect the vulnerable immunocompromised host.
Substances chimiques
COVID-19 Vaccines
0
Influenza Vaccines
0
Adjuvants, Immunologic
0
Antibodies, Viral
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14051Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Brunham RC, Coombs KM. In celebration of the 200th anniversary of Edward Jenner's Inquiry into the causes and effects of the variolae vaccinae. Can J Infect Dis. 1998;9(5):310-313.
Desmond A, Offit PA. On the shoulders of giants - from Jenner's cowpox to mRNA Covid vaccines. N Engl J Med. 2021;384(12):1081-1083.
Minor PD. Live attenuated vaccines: historical successes and current challenges. Virology. 2015;479-480:379-392.
McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-04):1-34.
Lee J, Arun Kumar S, Jhan YY, Bishop CJ. Engineering DNA vaccines against infectious diseases. Acta Biomater. 2018;80:31-47.
Danziger-Isakov L, Kumar D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13563.
Centers for Disease Control and Prevention. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012;61(40):816-819.
Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2018;67(1):1-31.
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261-279.
Hill A, Beitelshees M, Pfeifer BA. Vaccine delivery and immune response basics. Methods Mol Biol. 2021;2183:1-8.
Ringel O, Vieillard V, Debre P, Eichler J, Buning H, Dietrich U. The hard way towards an antibody-based HIV-1 Env vaccine: lessons from other viruses. Viruses. 2018;10(4):197.
Mesin L, Ersching J, Victora GD. Germinal center B cell dynamics. Immunity. 2016;45(3):471-482.
Astronomo RD, Burton DR. Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov. 2010;9(4):308-324.
Wiseman AC. Immunosuppressive medications. Clin J Am Soc Nephrol. 2016;11(2):332-343.
Zhang H, Weyand CM, Goronzy JJ. Hallmarks of the aging T-cell system. FEBS J. 2021;288(24):7123-7142.
Chong PP, Avery RK. A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients. Clin Ther. 2017;39(8):1581-1598.
Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: understanding the structure and mechanism of adjuvanticity. Vaccine. 2019;37(24):3167-3178.
Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004;4(4):249-258.
Zhang X, Zhang Z, Xia N, Zhao Q. Carbohydrate-containing nanoparticles as vaccine adjuvants. Expert Rev Vaccines. 2021;20(7):797-810.
Nanishi E, Dowling DJ, Levy O. Toward precision adjuvants: optimizing science and safety. Curr Opin Pediatr. 2020;32(1):125-138.
Eckerle I, Rosenberger KD, Zwahlen M, Junghanss T. Serologic vaccination response after solid organ transplantation: a systematic review. PLoS One. 2013;8(2):e56974.
Cowan M, Chon WJ, Desai A, et al. Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients. Transplantation. 2014;97(8):846-853.
Egli A, Humar A, Widmer LA, et al. Effect of immunosuppression on T-helper 2 and B-cell responses to influenza vaccination. J Infect Dis. 2015;212(1):137-146.
Rambal V, Muller K, Dang-Heine C, et al. Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients. Med Microbiol Immunol. 2014;203(1):35-45.
Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25.
Orcurto A, Pascual M, Hoschler K, Aubert V, Meylan P, Manuel O. Impact of anti-T-cell therapy in the immunogenicity of seasonal influenza vaccine in kidney transplant recipients. Transplantation. 2012;94(6):630-636.
Gangappa S, Wrammert J, Wang D, et al. Kinetics of antibody response to influenza vaccination in renal transplant recipients. Transpl Immunol. 2019;53:51-60.
Natori Y, Shiotsuka M, Slomovic J, et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin Infect Dis. 2018;66(11):1698-1704.
L'Huillier AG, Ferreira VH, Hirzel C, et al. Cell-mediated immune responses after influenza vaccination of solid organ transplant recipients: secondary outcomes analyses of a randomized controlled trial. J Infect Dis. 2020;221(1):53-62.
Baluch A, Humar A, Eurich D, et al. Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant. 2013;13(4):1026-1033.
GiaQuinta S, Michaels MG, McCullers JA, et al. Randomized, double-blind comparison of standard-dose vs. high-dose trivalent inactivated influenza vaccine in pediatric solid organ transplant patients. Pediatr Transplant. 2015;19(2):219-228.
Grohskopf LA, Blanton LH, Ferdinands JM, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2022-23 influenza season. MMWR Recomm Rep. 2022;71(1):1-28.
Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10(8):521-526.
Harboe ZB, Modin D, Gustafsson F, et al. Effect of influenza vaccination in solid organ transplant recipients: a nationwide population-based cohort study. Am J Transplant. 2022;21(7):2509-2521.
Chow KM, Law MC, Leung CB, Szeto CC, Li PK. Antibody response to hepatitis B vaccine in end-stage renal disease patients. Nephron Clin Pract. 2006;103(3):c89-c93.
Dominguez M, Barcena R, Garcia M, Lopez-Sanroman A, Nuno J. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl. 2000;6(4):440-442.
Mulley WR, Le ST, Ives KE. Primary seroresponses to double-dose compared with standard-dose hepatitis B vaccination in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant. 2017;32(1):136-143.
Grob PJ, Binswanger U, Zaruba K, et al. Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients. Antiviral Res. 1983;3(1):43-52.
Jacobson IM, Jaffers G, Dienstag JL, et al. Immunogenicity of hepatitis B vaccine in renal transplant recipients. Transplantation. 1985;39(4):393-395.
Carey W, Pimentel R, Westveer MK, Vogt D, Broughan T. Failure of hepatitis B immunization in liver transplant recipients: results of a prospective trial. Am J Gastroenterol. 1990;85(12):1590-1592.
Galar A, Engelson BA, Kubiak DW, et al. Serologic response to hepatitis B vaccination among lung transplantation candidates. Transplantation. 2014;98(6):676-679.
Friedrich P, Sattler A, Muller K, Nienen M, Reinke P, Babel N. Comparing humoral and cellular immune response against HBV vaccine in kidney transplant patients. Am J Transplant. 2015;15(12):3157-3165.
Manley HJ, Aweh G, Frament J, Ladik V, Lacson EK. A real world comparison of HepB (Engerix-B(R)) and HepB-CpG (Heplisav-B(R)) vaccine seroprotection in patients receiving maintenance dialysis. Nephrol Dial Transplant. 2023;38:447-454.
Amjad W, Alukal J, Zhang T, Maheshwari A, Thuluvath PJ. Two-dose hepatitis B vaccine (Heplisav-B) results in better seroconversion than three-dose vaccine (Engerix-B) in chronic liver disease. Dig Dis Sci. 2021;66(6):2101-2106.
Bruxvoort K, Slezak J, Huang R, et al. Association of number of doses with hepatitis B vaccine series completion in US adults. JAMA Netw Open. 2020;3(11):e2027577.
Cunningham AL, Heineman T. Vaccine profile of herpes zoster (HZ/su) subunit vaccine. Expert Rev Vaccines. 2017;16(7):1-10.
Vink P, Ramon Torrell JM, Sanchez Fructuoso A, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin Infect Dis. 2020;70(2):181-190.
Hirzel C, L'Huillier AG, Ferreira VH, et al. Safety and immunogenicity of adjuvanted recombinant subunit herpes zoster vaccine in lung transplant recipients. Am J Transplant. 2021;21(6):2246-2253.
L'Huillier AG, Hirzel C, Ferreira VH, et al. Evaluation of recombinant herpes zoster vaccine for primary immunization of varicella-seronegative transplant recipients. Transplantation. 2021;105(10):2316-2323.
Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the advisory committee on immunization practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109-117.
Musher DM, Rodriguez-Barradas MC. Pneumococcal Vaccination in Adults. UpToDate; 2022.
Centers for Disease Control and Prevention. Global Viral Hepatitis: Millions of People are Affected. Centers for Disease Control and Prevention; 2022. Updated July 19, 2021. Accessed 14 Sept 2022. https://www.cdc.gov/hepatitis/global/index.htm
Page K, Melia MT, Veenhuis RT, et al. Randomized trial of a vaccine regimen to prevent chronic HCV infection. N Engl J Med. 2021;384(6):541-549.
World Health Organization. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021. World Health Organization; 2022. Published 2021. Accessed 14 Sept 2022. https://www.who.int/publications/i/item/9789240027077
Cox A, Sulkowski M, Sugarman J. Ethical and practical issues associated with the possibility of using controlled human infection trials in developing a hepatitis C virus vaccine. Clin Infect Dis. 2020;71(11):2986-2990.
Thomas DL. Global elimination of chronic hepatitis. N Engl J Med. 2019;380(21):2041-2050.
Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13512.
Diamond DJ, La Rosa C, Chiuppesi F, et al. A fifty-year odyssey: prospects for a cytomegalovirus vaccine in transplant and congenital infection. Expert Rev Vaccines. 2018;17(10):889-911.
Aldoss I, La Rosa C, Baden LR, et al. Poxvirus vectored cytomegalovirus vaccine to prevent cytomegalovirus viremia in transplant recipients: a phase 2, randomized clinical trial. Ann Intern Med. 2020;172(5):306-316.
Gruber MF. Current status of monkeypox vaccines. NPJ Vaccines. 2022;7(1):94.
Centers for Disease Control. Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Monkeypox Outbreak. Centers for Disease Control; 2022. Accessed 14 Sept 2022. https://www.cdc.gov/poxvirus/monkeypox/health-departments/vaccine-considerations.html
Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther. 2010;4:71-79.
Nordic B. JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non-replicating) Suspension for Subcutaneous Injection. Federal Drug Administration; 2022. Accessed 2022. https://www.fda.gov/media/131078/download
Overton ET, Stapleton J, Frank I, et al. Safety and immunogenicity of modified vaccinia Ankara-Bavarian Nordic smallpox vaccine in vaccinia-naive and experienced human immunodeficiency virus-infected individuals: an open-label, controlled clinical phase II trial. Open Forum Infect Dis. 2015;2(2):ofv040.
Kew J. Africa, Where Monkeypox Is Endemic, Gets No Vaccines. US ed. Bloomberg; 2022. https://www.bloomberg.com/news/articles/2022-07-28/africa-falling-behind-on-monkeypox-vaccines-as-virus-spreads?leadSource=uverify%20wall
Tai W, Zhang X, Drelich A, et al. A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 2020;30(10):932-935.
Huo J, Le Bas A, Ruza RR, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27(9):846-854.
Alameh MG, Tombacz I, Bettini E, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54(12):2877-2892.e2877.
Yanis A, Haddadin Z, Spieker AJ, et al. Humoral and cellular immune responses to the SARS-CoV-2 BNT162b2 vaccine among a cohort of solid organ transplant recipients and healthy controls. Transpl Infect Dis. 2022;24(1):e13772.
Manothummetha K, Chuleerarux N, Sanguankeo A, et al. Immunogenicity and risk factors associated with poor humoral immune response of SARS-CoV-2 vaccines in recipients of solid organ transplant: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(4):e226822.
Galmiche S, Luong Nguyen LB, Tartour E, et al. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect. 2022;28(2):163-177.
Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA. 2021;325(21):2204-2206.
Stumpf J, Siepmann T, Lindner T, et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health Eur. 2021;9:100178.
Hall VG, Ferreira VH, Ierullo M, et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. Am J Transplant. 2021;21(12):3980-3989.
Sattler A, Schrezenmeier E, Weber UA, et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021;131(14).
Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med. 2021;385(7):661-662.
Peled Y, Ram E, Lavee J, et al. Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience. J Heart Lung Transplant. 2022;41(2):148-157.
Benotmane I, Gautier G, Perrin P, et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021;326(11):1063.
Havlin J, Svorcova M, Dvorackova E, et al. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients. J Heart Lung Transplant. 2021;40(8):754-758.
Werbel WA, Boyarsky BJ, Ou MT, et al. Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Ann Intern Med. 2021;174(9):1330-1332.
Hall VG, Ferreira VH, Ku T, et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients. N Engl J Med. 2021;385(13):1244-1246.
Kumar D, Ferreira VH, Hall VG, et al. Neutralization of SARS-CoV-2 variants in transplant recipients after two and three doses of mRNA-1273 vaccine: secondary analysis of a randomized trial. Ann Intern Med. 2022;175(2):226-233.
Alejo JL, Mitchell J, Chiang TP, et al. Six-month antibody kinetics and durability in SARS-CoV-2 mRNA vaccinated solid organ transplant recipients. Transplantation. 2022;106(1):e109-e110.
Sakuraba A, Luna A, Micic D. A systematic review and meta-analysis of serologic response following coronavirus disease 2019 (COVID-19) vaccination in solid organ transplant recipients. Viruses. 2022;14(8):1822.
Kumar D, Hu Q, Samson R, et al. Neutralization against omicron variant in transplant recipients after three doses of mRNA vaccine. Am J Transplant. 2022;22(8):2089-2093.
Benning L, Morath C, Bartenschlager M, et al. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. Am J Transplant. 2022;22(7):1873-1883.
Karaba AH, Johnston TS, Aytenfisu TY, et al. A fourth dose of COVID-19 vaccine does not induce neutralization of the omicron variant among solid organ transplant recipients with suboptimal vaccine response. Transplantation. 2022;106(7):1440-1444.
Abedon AT, Teles MS, Alejo JL, et al. Improved antibody response after a fifth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. Transplantation. 2022;106(5):e262-e263.
Boyarsky BJ, Chiang TP, Ou MT, et al. Antibody response to the Janssen COVID-19 vaccine in solid organ transplant recipients. Transplantation. 2021;105(8):e82-e83.
Chang A, Alejo JL, Abedon AT, et al. Antibody response to an mRNA SARS-CoV-2 vaccine following initial vaccination with Ad.26.COV2.S in solid organ transplant recipients: a case series. Transplantation. 2022;106(2):e161-e162.
Schmidt T, Klemis V, Schub D, et al. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Am J Transplant. 2021;21(12):3990-4002.
Thomson T, Prendecki M, Gleeson S, et al. Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients. EClinicalMedicine. 2022;53:101642.
Medina-Pestana J, Almeida Viana L, Nakamura MR, et al. immunogenicity after a heterologous BNT262b2 versus homologous booster in kidney transplant recipients receiving 2 doses of CoronaVac vaccine: a prospective cohort study. Transplantation. 2022;106(10):2076-2084.
Cristelli MP, Nakamura MR, Viana LA, Tedesco-Silva H, Medina-Pestana J. The fourth dose of CoronaVac vaccine results in a small increase of seroconversion and antibody values among kidney transplant recipients. Transplantation. 2022;106(9):e420-e421.
Klemis V, Schmidt T, Schub D, et al. Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. Nat Commun. 2022;13(1):4710.
Chiang TP, Alejo JL, Mitchell J, et al. Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination. Am J Transplant. 2022;22(9):2254-2260.
Mrak D, Sieghart D, Simader E, et al. Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. Nat Commun. 2022;13(1):5362.
Benotmane I, Gautier-Vargas G, Cognard N, et al. Prediction of vaccine response and development of a personalized anti-SARS-CoV-2 vaccination strategy in kidney transplant recipients: results from a large single-center study. J Pers Med. 2022;12(7):1107.
Baron F, Canti L, Arien KK, et al. Insights from early clinical trials assessing response to mRNA SARS-CoV-2 vaccination in immunocompromised patients. Front Immunol. 2022;13:827242.
Costard-Jackle A, Schramm R, Fischer B, et al. Third dose of the BNT162b2 vaccine in cardiothoracic transplant recipients: predictive factors for humoral response. Clin Res Cardiol. 2022;1-11.
Mitchell J, Chiang TP, Alejo JL, et al. Effect of mycophenolate mofetil dosing on antibody response to SARS-CoV-2 vaccination in heart and lung transplant recipients. Transplantation. 2022;106(5):e269-e270.
Tang K, Wu X, Luo Y, Wei Z, Feng L, Wu L. Meta-analysis of immunologic response after COVID-19 mRNA vaccination in solid organ transplant recipients. J Infect. 2022;84(5):e73-e75.
Bae S, Alejo JL, Chiang TPY, et al. mTOR inhibitors, mycophenolates, and other immunosuppression regimens on antibody response to SARS-CoV-2 mRNA vaccines in solid organ transplant recipients. Am J Transplant. 2022;22(12):3137-3142.
Lederer K, Bettini E, Parvathaneni K, et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell. 2022;185(6):1008-1024.e1015.
Ravanan R, Mumford L, Ushiro-Lumb I, et al. Two doses of SARS-CoV-2 vaccines reduce risk of death due to COVID-19 in solid organ transplant recipients: preliminary outcomes from a UK Registry Linkage Analysis. Transplantation. 2021;105(11):e263-e264.
Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021;70(44):1553-1559.
Callaghan CJ, Mumford L, Curtis RMK, et al. Real-world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against SARS-CoV-2 in solid organ and islet transplant recipients. Transplantation. 2022;106(3):436-446.
Aslam S, Liu J, Sigler R, et al. Coronavirus disease 2019 vaccination is protective of clinical disease in solid organ transplant recipients. Transpl Infect Dis. 2022;24(2):e13788.
Bestard O, Jouve T, Castells L, et al. Reconciling short-term clinical and immunological outcomes of SARS-CoV-2 vaccination in solid organ transplant recipients. Am J Transplant. 2022;22(2):673-675.
Bollineni S, Mahan LD, Duncan P, et al. Characteristics and outcomes among vaccinated lung transplant patients with breakthrough COVID-19. Transpl Infect Dis. 2022;24(2):e13784.
Qin CX, Moore LW, Anjan S, et al. Risk of breakthrough SARS-CoV-2 infections in adult transplant recipients. Transplantation. 2021;105(11):e265-e266.
Hedvat J, Lange NW, Salerno DM, et al. COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era. Am J Transplant. 2022;22(11):2682-2688.
Pereira B, Xu XN, Akbar AN. Targeting inflammation and immunosenescence to improve vaccine responses in the elderly. Front Immunol. 2020;11:583019.
Grupper A, Rabinowich L, Schwartz D, et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Am J Transplant. 2021;21(8):2719-2726.
Chavarot N, Ouedrani A, Marion O, et al. Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 injections of mRNA vaccine in kidney transplant recipients treated with belatacept. Transplantation. 2021;105(9):e94-e95.
Noble J, Langello A, Bouchut W, Lupo J, Lombardo D, Rostaing L. Immune response post-SARS-CoV-2 mRNA vaccination in kidney transplant recipients receiving belatacept. Transplantation. 2021;105(11):e259-e260.
Ou MT, Boyarsky BJ, Chiang TPY, et al. Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking belatacept. Transplantation. 2021;105(9):2119-2123.
Morena L, Al Jurdi A, Azzi J, Fishman J, Riella LV. Factors associated with reduced anti-SARS-CoV-2 antibody responses after mRNA vaccination in kidney transplant recipients on belatacept. Kidney Int Rep. 2022;7(11):2513-2516.
Haskin O, Ashkenazi-Hoffnung L, Ziv N, et al. Serological response to the BNT162b2 COVID-19 mRNA vaccine in adolescent and young adult kidney transplant recipients. Transplantation. 2021;105(11):e226-e233.
Schietzel S, Anderegg M, Limacher A, et al. Humoral and cellular immune responses on SARS-CoV-2 vaccines in patients with anti-CD20 therapies: a systematic review and meta-analysis of 1342 patients. RMD Open. 2022;8(1):e002036.